Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes

Gummesson, Anders; Nyman, Elisabeth; Knutsson, Mikael; Karpefors, Martin

doi:10.1111/dom.12971

Cited by 129 publications

(118 citation statements)

References 71 publications

(75 reference statements)

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…This goes in sync with a research by Gummesson et al, which mentioned that weight loss in the overweight population is consistently associated with HbA1c, in a dose dependent manner. (Gummesson et al, 2017) We also found a reduction in the patients who were on these allopathic drugs. This indicates that CDC may be one of the factors associated with the decrease in load of medications in DM patients, and also helps them in avoiding the potential adverse effects of the allopathic medications.…”

Section: Resultssupporting

confidence: 54%

Effect of Comprehensive Diabetes Care on Glycaemic Control with Reduction in Dependency of Oral Hypoglycaemic Medicines in Pre-obese Diabetic Patients: A Retrospective Study

Sane¹,

Naik²,

Khair³

et al. 2018

Int.J.Curr.Res.Aca.Rev.

View full text Add to dashboard Cite

Article Info Although multiple new drugs are coming out in the market, India has the 2 nd highest number of diabetics in the world.The aim of this study was to evaluate effects of Comprehensive Diabetes Care (CDC) on Glycosylated haemoglobin (HbA1c) and metabolic parameters in pre-obese diabetic patients. In this retrospective study, data of pre-obese DM patients who had received 6 CDC sittings over 90 days in the outpatient departments (OPDs) at Madhavbaug clinics was collected between May 2013 to April 2018. Demographic and co-morbidity details were noted. HbA1c, body mass index (BMI), abdominal girth, systolic and diastolic blood pressure (SBP, DBP), dependency on medications were assessed on days 1 and 90 of CDC. The patients followed a specific low-calorie diet plan during the study. 89 participants, (52 males, 37 females) were enrolled. Mean HbA1c measured at day 90 was significantly lower than that on day 1 (6.86 ± 1.24 vs 9.02 ± 1.79, p<0.001). Mean BMI was significantly reduced on day 90 when compared to baseline (25.39 ± 1.53 vs 27.24 ± 1.33, p<0.001). Abdominal girth was significantly decreased on day 90 compared to baseline (91.64 ± 6.26 vs 97.12 ± 7.03, p<0.001). SBP (122.83 ± 13.56 vs 131.60 ± 16.10, p<0.001) and DBP (77.02 ± 6.81 vs 81.75 ± 9.43, p<0.001) were also significantly decreased after 90 days. Dependency on concomitant medicines was reduced. Glycaemic control and metabolic parameters significantly improved after 90-day CDC treatment. Reduction in blood pressure and intake of concomitant medications were also noted.

show abstract

Section: Resultssupporting

confidence: 54%

Effect of Comprehensive Diabetes Care on Glycaemic Control with Reduction in Dependency of Oral Hypoglycaemic Medicines in Pre-obese Diabetic Patients: A Retrospective Study

Sane¹,

Naik²,

Khair³

et al. 2018

Int.J.Curr.Res.Aca.Rev.

View full text Add to dashboard Cite

show abstract

“…Weight loss can lead to a reduction in obesity‐related complications, including the risk of developing diabetes . In overweight (body mass index [BMI] ≥25 kg/m 2 and <30 kg/m 2 ) or obese people (BMI ≥30 kg/m 2 ) who have progressed to type 2 diabetes (T2D), weight loss is associated with reductions in glycated haemoglobin (HbA1c), improvements in CVD risk factors and reductions in mortality …”

Section: Introductionmentioning

confidence: 99%

“…[5][6][7] In overweight (body mass index [BMI] ≥25 kg/m 2 and-<30 kg/m 2 ) or obese people (BMI ≥30 kg/m 2 ) who have progressed to type 2 diabetes (T2D), weight loss is associated with reductions in glycated haemoglobin (HbA1c), improvements in CVD risk factors and reductions in mortality. [8][9][10] Weight reduction through lifestyle interventions alone can be challenging. 11 Options for effective pharmacological treatments are limited, and those available require daily dosing.…”

Section: Introductionmentioning

confidence: 99%

Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study

Pratley

Kang

Trautmann

et al. 2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimTo evaluate the safety of efpeglenatide, a long‐acting glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), and its effects on body weight management in adults without diabetes.Materials and methodsIn this phase II, randomized, placebo‐controlled, double‐blind trial, participants with a body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 with comorbidity were randomized 1:1:1:1:1 to efpeglenatide (4 mg once weekly, 6 mg once weekly, 6 mg once every 2 wk, or 8 mg once every 2 wk; n = 237) or placebo (n = 60) in combination with a hypocaloric diet. The primary endpoint was body weight change from baseline after 20 wk of treatment, assessed using a mixed‐effect model with repeated measures with an unstructured covariance matrix over all post‐screening visits; treatment comparisons were based on least squares mean estimates.ResultsOver 20 wk, all doses of efpeglenatide significantly reduced body weight from baseline versus placebo (P < 0.0001), with placebo‐adjusted reductions ranging between −6.3 kg (6 mg once every 2 wk) and −7.2 kg (6 mg once weekly). Greater proportions of efpeglenatide‐treated participants had body weight loss of ≥5% or ≥10% versus placebo (P < 0.01, all comparisons). Efpeglenatide led to significant improvements in glycaemic variables (fasting plasma glucose and glycated haemoglobin) and lipid profiles (cholesterol, triglycerides) versus placebo. Rates of study discontinuations as a result of adverse events ranged from 5% to 19% with efpeglenatide. Gastrointestinal effects were the most common treatment‐emergent adverse events.ConclusionsEfpeglenatide once weekly and once every 2 wk led to significant body weight reduction and improved glycaemic and lipid variables versus placebo. It was also well tolerated for weight management in adults without diabetes.

show abstract

“…Снижение массы тела сопровождается повышением чувствительности тканей к инсулину, улучшением метаболизма липидов, устранением латентного воспаления и, соответственно, играет важнейшую роль в профилактике СД2 и снижении риска его осложнений. Как показал математический анализ консервативных методов веде-ния больных СД2, каждый 1 кг снижения массы тела сопровождается уменьшением HbA 1c на 0,1% [10].…”

Section: оригинальная работаunclassified

Rational approach to patients treatment with type 2 diabetes and obesity: results of the All-Russian observational program «AURORA»

et al. 2019

View full text Add to dashboard Cite

Background: As in many other developed nations, the problem of obesity and type 2 diabetes is acute in Russia. In Russia, the only combination of sibutramine and metformine (ReduxinMet) is authorized to reduce body mass and prevention development of type 2 diabetes mellitus or its complication. The article presents the results of the observational program AVRORA. Aim: Evaluation of the effectiveness and safety of ReduxinMet (sibutramine + microcrystalline cellulose + Metformin) in patients with type 2 diabetes and alimentary obesity in routine clinical practice. Materials methods: The observational program AVRORA was conducted from September 2016 to October 2017 under the auspices of the Endocrinological Scientific Center and the Russian Association of Endocrinologists. The AVRORA program was a multicenter, non-interventional study of patients to whom the attending physicians prescribed ReduxinMet, a set (tablets + capsules), in accordance with the instruction for medical use as part of routine clinical practice. The treated group included patients of both sexes, aged 1865 years, with an established diagnosis of obesity in combination with type 2 diabetes. The duration of the drug usage was determined by the attending physician and was up to 6 months. ReduxineMet was prescribed in addition to the existing glucose-lowering therapy, the dose of metformin was adjusted to the patient's needs. Results: The AVRORA study was attended by 259 doctors and 5,812 patients in 240 medical institutions from 12 cities of the Russian Federation. The average age of patients was 46.6 10.5 years, the ratio of male / female -24% / 76%. The decreasing of BMI during 6 months of the therapy amounted to 5.4 2.3 kg / m2 (on average, 15.1 6.4 kg). After 3 months of the therapy 81.6% of patients achieved clinically significant weight loss of 10.6% or more. The average decrease in waist circumference during 6 months of therapy was 13.8 7.4 cm. A decrease of indicators of glycemic control and lipid metabolism right up to the target values was observed. Conclusions: In AVRORA study it was shown that addition of ReduxineMet (sibutramine+ microcrystalline cellulose+metformine) to the complex therapy of the diabetes in combination with obesity according to approved indications is safe and effective for long-term treatment in regards to weight loss, regulation of lipemic index, glucose profile and quality of life.

show abstract

Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes

Cited by 129 publications

References 71 publications

Effect of Comprehensive Diabetes Care on Glycaemic Control with Reduction in Dependency of Oral Hypoglycaemic Medicines in Pre-obese Diabetic Patients: A Retrospective Study

Effect of Comprehensive Diabetes Care on Glycaemic Control with Reduction in Dependency of Oral Hypoglycaemic Medicines in Pre-obese Diabetic Patients: A Retrospective Study

Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study

Rational approach to patients treatment with type 2 diabetes and obesity: results of the All-Russian observational program «AURORA»

Contact Info

Product

Resources

About